Rheumatic diseases comprise a variety of systemic autoimmune diseases and lead to enormous economic and health costs worldwide. Multiple organ involvements develop in most of the leading rheumatic diseases including rheumatoid arthritis, systemic lupus erythematosus, Sjo¨gren's Syndrome, systemic vasculitis, etc. Accumulating shreds of evidence suggest that multiple factors are associated with the development and progression of multi-organ damages in rheumatic diseases, including but not limited to variances in genetic susceptibility, heterogeneity of immune responses and environmental factors. Despite significant improvements in diagnosis and treatment strategies, early diagnosis or prediction and precise treatment continue to be great challenges due to the lack of effective biomarkers and practical predictive models supported by solid clinical evidence. Identification of novel biomarkers associated with clinical or molecular subtypes and prognosis of rheumatic diseases is essential for early prediction and diagnosis of specific organ involvement, disease surveillance and precise treatment. The comprehensive application of multi-omics biomarker screening, imaging techniques and clinical stratification modeling can be used as new diagnostic and therapeutic tools for rheumatic diseases.
This research topic will focus on novel biomarkers for clinical and molecular stratification of organ involvement in rheumatic diseases that can be used for early diagnosis/prediction or precise treatment of organ involvement in rheumatic diseases. We welcome submissions of Original Research, Reviews, Clinical Trials, Meta-Analysis or Systemic Reviews, Case series and Short Reports, on the subtopics of the following, but are not limited to:
? Novel clinical biomarker screening and validation for prediction, diagnosis and precise treatment of organ involvement in rheumatic diseases.
? Bioinformatics-based predictive models for the prediction and early diagnosis of organ damage development of various rheumatic diseases including autoimmune and inflammatory conditions.
? Imaging biomarkers that could be utilized for the identification of diagnosis, treatment decision, and progression surveillance of organ involvement in various rheumatic diseases.
? The pre-clinical and clinical study of precise therapeutical strategies for the treatment of organ damage in rheumatic diseases based on clinical and molecular stratification of rheumatic diseases.
Rheumatic diseases comprise a variety of systemic autoimmune diseases and lead to enormous economic and health costs worldwide. Multiple organ involvements develop in most of the leading rheumatic diseases including rheumatoid arthritis, systemic lupus erythematosus, Sjo¨gren's Syndrome, systemic vasculitis, etc. Accumulating shreds of evidence suggest that multiple factors are associated with the development and progression of multi-organ damages in rheumatic diseases, including but not limited to variances in genetic susceptibility, heterogeneity of immune responses and environmental factors. Despite significant improvements in diagnosis and treatment strategies, early diagnosis or prediction and precise treatment continue to be great challenges due to the lack of effective biomarkers and practical predictive models supported by solid clinical evidence. Identification of novel biomarkers associated with clinical or molecular subtypes and prognosis of rheumatic diseases is essential for early prediction and diagnosis of specific organ involvement, disease surveillance and precise treatment. The comprehensive application of multi-omics biomarker screening, imaging techniques and clinical stratification modeling can be used as new diagnostic and therapeutic tools for rheumatic diseases.
This research topic will focus on novel biomarkers for clinical and molecular stratification of organ involvement in rheumatic diseases that can be used for early diagnosis/prediction or precise treatment of organ involvement in rheumatic diseases. We welcome submissions of Original Research, Reviews, Clinical Trials, Meta-Analysis or Systemic Reviews, Case series and Short Reports, on the subtopics of the following, but are not limited to:
? Novel clinical biomarker screening and validation for prediction, diagnosis and precise treatment of organ involvement in rheumatic diseases.
? Bioinformatics-based predictive models for the prediction and early diagnosis of organ damage development of various rheumatic diseases including autoimmune and inflammatory conditions.
? Imaging biomarkers that could be utilized for the identification of diagnosis, treatment decision, and progression surveillance of organ involvement in various rheumatic diseases.
? The pre-clinical and clinical study of precise therapeutical strategies for the treatment of organ damage in rheumatic diseases based on clinical and molecular stratification of rheumatic diseases.
